CompletedNot Applicable

The Affect Of An Anti-Embolism Stocking Protocol

Turkey (Türkiye)40 participantsStarted 2019-10-16

Plain-language summary

This study was conducted to determine the effect of anti-embolism stocking (AES) use protocol affected the development of early venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA). The randomized controlled single-blind intervention study included 40 patients (Experimental Group: 20, Control Group: 20) who underwent TKA surgery in a university hospital's Orthopedics and Traumatology clinic between 2019 and 2021. While the experimental group received the AES protocol one day before the operation and continued until the 10 th day after the operation, the control group received AES on the 0 th day after the operation and remained in the patient until the 21st day after the operation. In the study, a "Data Collection Form" with DVT and PE signs and symptoms was used.

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Older than 18 years old, * No harm in wearing AES, * Patients who agreed to participate in the study. Exclusion Criteria: * Bilateral TKA used patients, * Having excess leg edema, pulmonary edema, heart failure, * Having leg ischemia, * Having skin graft, * An open wound in the area where AES will be applied, * Having arterial and venous vessel disease, * Having neuropathy, * Having cellulite on the patient's leg to whom AES will be applied, * Having an infection such as fasciitis or panniculitis, * Those who declare that they will not use AES for ten days in accordance with the recommendations.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Distribution of Descriptive Characteristics and Surgical Information of the Patients

Timeframe: Three weeks

VTE Evaluation Form

Timeframe: Three weeks

Trial details

NCT IDNCT06616376

SponsorCukurova University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-02-17

View on ClinicalTrials.gov More Venous Thromboembolism trials